Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BRUKINSA | BeOne Medicines | N-213217 RX | 2019-11-14 | 1 products, RLD, RS |
BRUKINSA | BeOne Medicines | N-218785 RX | 2025-06-10 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
brukinsa | New Drug Application | 2025-04-08 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
mantle-cell lymphoma | — | D020522 | C83.1 |
Expiration | Code | ||
---|---|---|---|
ZANUBRUTINIB, BRUKINSA, BEIGENE | |||
2030-01-19 | ODE-274 | ||
2028-09-14 | ODE-370 | ||
2028-08-31 | ODE-371 | ||
2026-11-14 | ODE-276 | ||
2026-01-19 | I-817 | ||
2024-11-14 | NCE | ||
2024-09-14 | I-874 | ||
2024-08-31 | I-871 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Zanubrutinib, Brukinsa, Beigene | |||
11786531 | 2043-01-19 | U-3715, U-3716, U-3717, U-3718, U-3719, U-3720 | |
11911386 | 2043-01-19 | U-3715, U-3716, U-3717, U-3718, U-3719, U-3720 | |
10927117 | 2037-08-15 | DS, DP | |
11591340 | 2037-08-15 | U-1745 , U-2145 , U-2537, U-2666 , U-3063 , U-3486 | |
11851437 | 2037-08-15 | DS, DP | |
11884674 | 2037-08-15 | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 | |
9447106 | 2034-04-22 | DS, DP | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 |
10570139 | 2034-04-22 | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 | |
11142528 | 2034-04-22 | DP | U-1745, U-2145, U-2537, U-2666, U-3063, U-3486 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 10 | 26 | 4 | 1 | 3 | 39 |
Lymphoid leukemia | D007945 | — | C91 | 7 | 20 | 4 | 1 | 3 | 32 |
Leukemia | D007938 | — | C95 | 9 | 18 | 4 | 1 | 2 | 31 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 17 | 78 | 12 | — | 10 | 111 |
B-cell lymphoma | D016393 | — | — | 14 | 40 | 5 | — | 2 | 56 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 8 | 37 | 3 | — | — | 46 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 8 | 18 | 5 | — | 2 | 29 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 7 | 9 | 2 | — | 2 | 17 |
Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 2 | 10 | 1 | — | 5 | 16 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 7 | 2 | — | 1 | 14 |
Neoplasms | D009369 | — | C80 | 10 | 6 | 1 | — | — | 12 |
Hodgkin disease | D006689 | — | C81 | — | 1 | 1 | — | — | 2 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Follicular lymphoma | D008224 | — | C82 | 4 | 15 | — | — | 2 | 19 |
Healthy volunteers/patients | — | — | — | 8 | 1 | — | — | — | 9 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 5 | — | — | — | 5 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 4 | — | — | — | 4 |
Recurrence | D012008 | — | — | 1 | 3 | — | — | — | 4 |
Syndrome | D013577 | — | — | 2 | 1 | — | — | — | 3 |
Intraocular lymphoma | D064090 | — | — | — | 2 | — | — | 1 | 3 |
Hemolytic anemia autoimmune | D000744 | EFO_1001264 | D59.10 | — | 3 | — | — | — | 3 |
Hematologic neoplasms | D019337 | — | — | 2 | 1 | — | — | — | 2 |
Therapeutics | D013812 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | — | 2 |
Preleukemia | D011289 | — | — | 2 | — | — | — | — | 2 |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 2 | — | — | — | — | 2 |
Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 2 | 2 |
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | — | 1 | 1 |
Supraventricular tachycardia | D013617 | — | I47.1 | — | — | — | — | 1 | 1 |
Mycoses | D009181 | — | B35-B49 | — | — | — | — | 1 | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 1 | 1 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | — | 1 | 1 |
Hidradenitis suppurativa | D017497 | — | L73.2 | — | — | — | — | 1 | 1 |
Mycosis fungoides | D009182 | — | C84.0 | — | — | — | — | 1 | 1 |
T-cell lymphoma cutaneous | D016410 | — | C84.A | — | — | — | — | 1 | 1 |
Drug common name | Zanubrutinib |
INN | zanubrutinib |
Description | Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1 |
PDB | — |
CAS-ID | 1651179-04-2 |
RxCUI | — |
ChEMBL ID | CHEMBL3936761 |
ChEBI ID | — |
PubChem CID | 135565884 |
DrugBank | DB15035 |
UNII ID | AG9MHG098Z (ChemIDplus, GSRS) |